Treatment of the Elderly When Cure is the Goal: The Influence of Age on Treatment Selection and Efficacy for Stage III Non-small Cell Lung Cancer Linda.

Slides:

Advertisements

Similar presentations

A Hole in the Heart Journal of Thoracic Oncology

Advertisements

Frances A Shepherd, MD, Rafael Rosell, MD Journal of Thoracic Oncology

A Clinical Prognostic Index for Patients Treated with Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21 Marie Florescu,

Sukki Cho, MD, Kyung-Min Ryu, MD, Yoon-Jin Hwang, MD, Eung Bae Lee, MD

Erlotinib or Docetaxel for Second-Line Treatment of Non-small Cell Lung Cancer: A Real-World Cost-Effectiveness Analysis Ian Cromwell, MSc, Kimberly.

Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies Sai-Hong Ignatius Ou, MD,

Elderly Patients with Advanced NSCLC in Phase III Clinical Trials: Are the Elderly Excluded from Practice-Changing Trials in Advanced NSCLC? Adrian G.

Characteristics and Outcomes of Small Cell Lung Cancer Patients Diagnosed During Two Lung Cancer Computed Tomographic Screening Programs in Heavy Smokers

Anxiety After Diagnosis Predicts Lung Cancer–Specific and Overall Survival in Patients With Stage III Non–Small Cell Lung Cancer: A Population-Based Cohort.

Accelerated hemithoracic radiation followed by extrapleural pneumonectomy for malignant pleural mesothelioma Marc de Perrot, MD, MSc, Ronald Feld, MD,

Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer Sai-Hong Ignatius Ou, MD, PhD, Jason.

Michael C. Roach, MD, Gregory M. M. Videtic, MD, CM, FRCPC, Jeffrey D

A prospective controlled trial of endobronchial ultrasound-guided transbronchial needle aspiration compared with mediastinoscopy for mediastinal lymph.

Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy

Outcomes of Second-Line Chemotherapy in Patients with Relapsed Extensive Small Cell Lung Cancer Sandra Froeschl, MD, Garth Nicholas, MD, FRCPC, Victor.

A Randomized Phase II Trial of Pemetrexed/Gemcitabine/Bevacizumab or Pemetrexed/Carboplatin/Bevacizumab in the First-Line Treatment of Elderly Patients.

Invasive Mediastinal Staging Guideline Concordance

Long-Term Outcome after En Bloc Resection of Non–Small-Cell Lung Cancer Invading the Pulmonary Sulcus and Spine Stéphane Collaud, MD, MSc, Thomas K.

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD

A Clinical Prognostic Index for Patients Treated with Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21 Marie Florescu,

Tumor Regression and Positional Changes in Non-small Cell Lung Cancer During Radical Radiotherapy Gerald Lim, MD, Andrea Bezjak, MD, CM, MSc, Jane Higgins,

Long-Term Outcome After Resection of Non-Small Cell Lung Cancer Invading the Thoracic Inlet Stéphane Collaud, MD, MS, Tiago Machuca, MD, PhD, Olaf Mercier,

Electronic Updates for JTO Readers

Yuzhao Wang, MD, Jonathan C. Yeung, MD, PhD, Waël C

IA05.01 Lung Cancer Cases Journal of Thoracic Oncology

Adjuvant Cisplatin and Vinorelbine for Completely Resected Non-small Cell Lung Cancer: Subgroup Analysis of the Lung Adjuvant Cisplatin Evaluation Jean-Yves.

A Phase I/II Study of GTI-2040 Plus Docetaxel as Second-Line Treatment in Advanced Non-small Cell Lung Cancer: A Study of the PMH Phase II Consortium

A Systematic Review and Canadian Consensus Recommendations on the Use of Biomarkers in the Treatment of Non-small Cell Lung Cancer Peter M. Ellis, MBBS,

The International Association for the Study of Lung Cancer International Staging Project on Lung Cancer Peter Goldstraw, MB, FRCS, John J. Crowley, PhD

Samuel J. Wang, MD, PhD, C David Fuller, MD, Charles R. Thomas, MD

Frank Detterbeck, MD Journal of Thoracic Oncology

Elderly Patients with Advanced NSCLC in Phase III Clinical Trials: Are the Elderly Excluded from Practice-Changing Trials in Advanced NSCLC? Adrian G.

Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration in the Management of Previously Treated Lung Cancer Masaki Anraku, MD, Andrew F. Pierre,

Intratumoral Lymphatic Vessel Involvement is an Invasive Indicator of Completely Resected Pathologic Stage I Non-small Cell Lung Cancer Masahiko Harada,

Effects of Chemotherapy on Survival of Elderly Patients with Small-Cell Lung Cancer: Analysis of the SEER-Medicare Database Laura C. Caprario, MD, MS,

Prognostic Factors for Cure, Recurrence and Long-Term Survival After Surgical Resection of Thymoma Najib Safieddine, MD, Geoffrey Liu, MD, Kris Cuningham,

The Applicability of the Proposed IASLC Staging Revisions to Small Cell Lung Cancer (SCLC) with Comparison to the Current UICC 6th TNM Edition Sai-Hong.

Chest Wall Pain and Rib Fracture after Stereotactic Radiotherapy for Peripheral Non- small Cell Lung Cancer Jon-Paul J. Voroney, PhD, MD, Andrew Hope,

A Hole in the Heart Journal of Thoracic Oncology

Daniel Morgensztern, MD, Boone Goodgame, MD, Maria Q

Experience from an American Association for Thoracic Surgery Foundation for Thoracic Surgery Training Fellowship: Lung transplantation in Toronto General.

Rachel Benamore, MB BChir, MRCP, FRCR, Frances A

Stereotactic Body Radiotherapy in Patients with Previous Pneumonectomy: Safety and Efficacy Robert Thompson, MD, Meredith Giuliani, MBBS, Mei Ling Yap,

Referral Patterns for Adjuvant Chemotherapy in Patients with Completely Resected Non-small Cell Lung Cancer Farrah Kassam, MD, Frances A. Shepherd, MD,

Efficacy and Safety of Bevacizumab-Based Therapy in Elderly Patients with Advanced or Recurrent Nonsquamous Non-small Cell Lung Cancer in the Phase III.

P3.02c-076 Correlation of Neutrophil to Lymphocyte Ratio (NLR) with Clinical Benefit from Checkpoint Inhibitors in Advanced Lung Cancer Alona Zer, Mike.

Patients with Advanced Non–Small Cell Lung Cancer: Are Research Biopsies a Barrier to Participation in Clinical Trials? Charles Lim, MD, Mike Sung, BSc,

High Risk for Thoracotomy but not Thoracoscopic Lobectomy

Trends in Stage Distribution for Patients with Non-small Cell Lung Cancer: A National Cancer Database Survey Daniel Morgensztern, MD, Shean Huey Ng,

The Prognostic Impact of Cigarette Smoking on Patients with Non-small Cell Lung Cancer Ryo Maeda, MD, Junji Yoshida, MD, PhD, Genichiro Ishii, MD, PhD,

Historical perspectives of The American Association for Thoracic Surgery: F. Griffith Pearson (1926–) Andrew Pierre, MD, Vivek Rao, MD, PhD, Shaf Keshavjee,

Immune-Modulating Vaccines in Non-small Cell Lung Cancer

Driven by Mutations: The Predictive Value of Mutation Subtype in EGFR-Mutated Non– Small Cell Lung Cancer Emily Castellanos, MD, Emily Feld, MD, Leora.

Bolstering the Case for Lobectomy in Stages I, II, and IIIA Small-Cell Lung Cancer Using the National Cancer Data Base Susan E. Combs, MA, Jacquelyn.

Adjuvant Chemotherapy for Non-small Cell Lung Cancer: Practice Patterns and Outcomes in the General Population of Ontario, Canada Christopher M. Booth,

Jie Huang, Juan Peng, Linlang Guo, MD, PhD

Recursive Partitioning Analysis Groups II–III Brain Metastases of Non-small Cell Lung Cancer: A Phase II Randomized Study Comparing Two Concurrent Chemoradiotherapy.

Ethnic Differences in the Management of Lung Cancer in New Zealand

International Thymic Malignancies Interest Group: A Way Forward

Risk Factors for Major Complications After Extrapleural Pneumonectomy for Malignant Pleural Mesothelioma Marc de Perrot, MD, Karen McRae, MD, Masaki.

Outcome of Multimodality Treatment for 188 Cases of Type B3 Thymoma

Plasma Biomarker Enrichment of Clinical Prognostic Indices in Malignant Pleural Mesothelioma Harvey I. Pass, MD, Chandra Goparaju, PhD, Osvaldo Espin-Garcia,

Stage I Non-small Cell Lung Cancer: Results for Surgery in a Patterns-of-Care Study in Sydney and for High-Dose Concurrent End-Phase Boost Accelerated.

Tumor Lysis Syndrome in Limited-Stage Small-Cell Lung Cancer

Treatment-by-Histology Interaction Analyses in Three Phase III Trials Show Superiority of Pemetrexed in Nonsquamous Non-small Cell Lung Cancer Giorgio.

Bortezomib Plus Gemcitabine/Carboplatin as First-Line Treatment of Advanced Non- small Cell Lung Cancer: A Phase II Southwest Oncology Group Study (S0339)

Nutrition During Trimodality Treatment in Stage III Non-small Cell Lung Cancer: Not Only Important for Underweight Patients Barbara S. van der Meij,

Effect of Tumor Size on Prognosis in Patients Treated with Radical Radiotherapy or Chemoradiotherapy for Non–Small Cell Lung Cancer: An Analysis of the.

A Review of First-Line Treatment for Small-cell Lung Cancer

Razvan Diaconescu, MD, Chantal Lafond, MD, Renaud Whittom, MD

Presentation transcript:

Treatment of the Elderly When Cure is the Goal: The Influence of Age on Treatment Selection and Efficacy for Stage III Non-small Cell Lung Cancer Linda E. Coate, MD, Christine Massey, MSc, Andrew Hope, MD, Adrian Sacher, MD, Katherine Barrett, MD, Andrew Pierre, MD, Natasha Leighl, MD, Anthony Brade, MD, Marc de Perrot, MD, Tom Waddell, MD, Geoffrey Liu, MD, Ronald Feld, MD, Ronald Burkes, MD, B. C. John Cho, MD, Gail Darling, MD, Alexander Sun, MD, Shaf Keshavjee, MD, Andrea Bezjak, MD, Frances A. Shepherd, MD, FRCPC Journal of Thoracic Oncology Volume 6, Issue 3, Pages 537-544 (March 2011) DOI: 10.1097/JTO.0b013e31820b8b9b Copyright © 2011 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 1 Overall survival according to age. A, Overall survival according to age—entire cohort. B, Overall survival according to age for nonsurgical bimodality therapy. C, Overall survival according to age—surgical multimodality therapy. Journal of Thoracic Oncology 2011 6, 537-544DOI: (10.1097/JTO.0b013e31820b8b9b) Copyright © 2011 International Association for the Study of Lung Cancer Terms and Conditions